Sort   by:  
 Page size 
UnknownThe effect of HLA genotype on disease onset and severity in CTLA-4 insufficiency.
Not available
S-EPMC11744039 | biostudies-literature
UnknownSelf-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation.
Not available
S-EPMC2193477 | biostudies-literature
UnknownChanges of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells.
Not available
S-EPMC4888655 | biostudies-literature
UnknownEfficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Not available
S-EPMC9647833 | biostudies-literature
UnknownThe ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial.
Not available
S-EPMC9573884 | biostudies-literature
UnknownBiochemical and cellular consequences of the antithrombin p.Met1? mutation identified in a severe thrombophilic family.
Not available
S-EPMC6145704 | biostudies-literature
UnknownEfficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Not available
S-EPMC8674139 | biostudies-literature
UnknownClinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Not available
S-EPMC3128214 | biostudies-literature
UnknownInfluence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.
Not available
S-EPMC11806368 | biostudies-literature
Unknown"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Not available
S-EPMC9061286 | biostudies-literature
Sort   by:  
 Page size